Protective effects of berberine against doxorubicin-induced cardiotoxicity in rats by inhibiting metabolism of doxorubicin

References

• Ahmed F, Urooj A. (2012). Cardioprotective activity of standardized extract of Ficus racemosa stem bark against doxorubicin-induced toxicity. Pharm Biol 50:468–73
   PubMed Web of Science ®Google Scholar
• Arafa MH, Mohammad NS, Atteia HH, et al. (2014). Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem 70:701–11
   PubMed Web of Science ®Google Scholar
• Bains OS, Grigliatti TA, Reid RE, et al. (2010). Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther 335:533–45
   PubMed Web of Science ®Google Scholar
• Bains OS, Karkling MJ, Grigliatti TA, et al. (2009). Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos 37:1107–14
   PubMed Web of Science ®Google Scholar
• Blanco JG, Leisenrinq WM, Gonzalez-Covarrubias VM, et al. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789–95
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, et al. (2009). Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267–85
   PubMed Web of Science ®Google Scholar
• Cecen E, Dost T, Culhaci N, et al. (2011). Protective effects of silymarin against doxorubicin-induced toxicity. Asian Pac J Cancer Prev 12:2697–704
   PubMed Web of Science ®Google Scholar
• Forrest GL, Akman S, Doroshow JH, et al. (1991). Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity. Mol Pharmacol 40:502–10
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Chee GL, Thampatty P, et al. (1999). The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Anticancer Drugs 10:47–54
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Yalowich JC, Ling Y, et al. (1996). The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 7:558–67
   PubMed Web of Science ®Google Scholar
• Herman EH, Zhang J, Chadwick DP, et al. (2000). Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 45:329–34
   PubMed Web of Science ®Google Scholar
• Lal S, Mahajan A, Chen WN, et al. (2010). Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11:115–28
   PubMed Web of Science ®Google Scholar
• Lau CW, Yao XQ, Chen ZY, et al. (2001). Cardiovascular actions of berberine. Cardiovasc Drug Rev 19:234–44
   PubMed Web of Science ®Google Scholar
• Lv X, Yu X, Wang Y, et al. (2012). Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression. PLoS One 7:e47351
   PubMedGoogle Scholar
• Matuszczyk A, Petersenn S, Bockisch A, et al. (2008). Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40:210–13
   PubMed Web of Science ®Google Scholar
• Menna P, Recalcati S, Cairo G, et al. (2007). An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:80–5
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229
   PubMed Web of Science ®Google Scholar
• Minotti G, Ronchi R, Salvatorelli E, et al. (2001). Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422–88
   PubMed Web of Science ®Google Scholar
• Mordente A, Meucci E, Martorana GE, et al. (2001). Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52:83–8
   PubMed Web of Science ®Google Scholar
• Mordente A, Minotti G, Martorana GE, et al. (2003). Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989–98
   PubMed Web of Science ®Google Scholar
• Olson RD, Mushlin PS, Brenner DE, et al. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585–9
   PubMed Web of Science ®Google Scholar
• Salvatorelli E, Menna P, Gonzalez Paz O, et al. (2012). Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin. J Pharmacol Exp Ther 341:474–83
   PubMed Web of Science ®Google Scholar
• Singal PK, Deally CM, Weinberg LE. (1987). Subcellular effects of adriamycin in the heart: a concise review. Cell Cardiol 19:817–28
   PubMed Web of Science ®Google Scholar
• Stěrba M, Popelová O, Vávrová A, et al. (2013). Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 18:899–929
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–79
   PubMed Web of Science ®Google Scholar
• Takemura G, Fujiwara H. (2007). Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330–52
   PubMed Web of Science ®Google Scholar
• Tallaj JA, Franco V, Rayburn BK, et al. (2005). Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24:2196–201
   PubMed Web of Science ®Google Scholar
• Tong N, Zhang J, Chen Y, et al. (2012). Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro. Oncol Lett 3:1263–7
   PubMed Web of Science ®Google Scholar
• Zeng XH, Zeng XJ, Li YY. (2003). Efficacy and safety of berberine for congestive heartfailure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92:173–6
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang J, Tong N, et al. (2011). Berberine attenuates doxorubicin-induced cardiotoxicity in mice. J Int Med Res 39:1720–7
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhou F, Wu X, et al. (2010). 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo. J Ethnopharmacol 128:615–22
   PubMed Web of Science ®Google Scholar
• Zhou F, Hao G, Zhang J, et al. (2014). Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism. Br J Pharmacol 2014; Epub ahead of print
   Google Scholar
• Zucchi R, Danesi R. (2003). Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anti-cancer Agents 3:151–71
   PubMedGoogle Scholar